Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-11-24-Speech-3-191"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-11-24"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20101124.15.3-191"2
lpv:hasSubsequent	lp_eu:2010-11-24-Speech-3-9632
lpv:speaker	lp:Jean-Luc Mélenchon2
lpv:spokenAs	vice-chair; AFET (2009-07-16--2011-10-04)3 unknown; Front de gauche pour changer d’Europe (2009-07-14--2014-06-30)3 substitute; CULT (2009-07-16--2012-01-18)3 substitute; Delegation for relations with the Maghreb countries and the Arab Maghreb Union (2009-09-16--2014-06-30)3 member; Delegation for relations with the Mercosur countries (2009-09-16--2014-06-30)3 member; EUL/NGL (2009-07-14--2014-06-30)3 member; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2014-06-30)3
lpv:translated text	"Not all the amendments made by this House to the proposal by the Commission and the Council are along the right lines. They adhere strictly to the principle of a single market in medicinal products and still view products available over the counter as goods like any others; the authors even end up talking of ‘consumers’ rather than patients. The amendments do not propose preventing pharmaceutical companies from producing information about their medicines for the general public. They do, however, have the virtue of seeking to enable the Member States to regulate as far as possible the dissemination of information published by those companies. In particular, they grant them the right to publicly condemn companies that publish information which is not in line with official State data or that disseminate it in a misleading fashion. That is better than nothing. I cannot, however, vote for such a weak text. I will therefore abstain."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph